1213 related articles for article (PubMed ID: 31539077)
21. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
22. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
Jiang W; Cheng H; Yu L; Zhang J; Wang Y; Liang Y; Lou F; Wang H; Cao S
Cancer Med; 2023 Mar; 12(6):6649-6658. PubMed ID: 36440695
[TBL] [Abstract][Full Text] [Related]
23. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
Shepherd FA; Lacas B; Le Teuff G; Hainaut P; Jänne PA; Pignon JP; Le Chevalier T; Seymour L; Douillard JY; Graziano S; Brambilla E; Pirker R; Filipits M; Kratzke R; Soria JC; Tsao MS;
J Clin Oncol; 2017 Jun; 35(18):2018-2027. PubMed ID: 28453411
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
25. Non-small-cell lung cancer patients harboring
Zhang C; Wang K; Lin J; Wang H
Future Oncol; 2022 Sep; 18(27):3031-3041. PubMed ID: 36065989
[TBL] [Abstract][Full Text] [Related]
26. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
27. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
Chen J; Zheng Q; Wang J; Zhang X; Lv Y
Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
[TBL] [Abstract][Full Text] [Related]
30. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
Mazzotta M; Filetti M; Occhipinti M; Marinelli D; Scalera S; Terrenato I; Sperati F; Pallocca M; Rizzo F; Gelibter A; Botticelli A; Scafetta G; Di Napoli A; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Fanciulli M; De Nicola F; Ciuffreda L; Goeman F; De Maria R; Vecchione A; Giusti R; Ciliberto G; Marchetti P; Maugeri-Saccà M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759236
[TBL] [Abstract][Full Text] [Related]
35. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
39. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
[TBL] [Abstract][Full Text] [Related]
40. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]